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524CD154 Expression Is Associated with Neutralizing
Antibody Titer Levels Postinfluenza Vaccination in
Stem Cell Transplant Patients and Healthy Adults
Aprille Seidel,1 David Smith,2 Edward Yung,1 Lia Aquino,3 Tumul Srivastava,1 Vinod Pullarkat,4
Ricardo Spielberger,4 Stephen J. Forman,4 Don J. Diamond1Weundertook aprospective longitudinal study toexaminehumoral andcellular immune responses to influenza
vaccination in hematopoietic cell transplant (HCT) patients and healthy adults. Healthy volunteers and HCT
patients hadblood samples taken prior to influenzavaccination and30, 90, and180days postvaccination. Serum
frompre- andpostvaccination time pointswere tested for influenzaA IgG and IgMby ELISA aswell as tested for
neutralizing antibody (NAb) titers via hemagluttination inhibition assay. Polychromatic flow cytometry was
used to examine CD41 T cells for levels of interferon (IFN)-g, tumor necrosis factor (TNF)-a, and CD154
(CD40 ligand) expression after stimulation with inactivated flu virus. In healthy subjects, we found a significant
increase in InfluenzaA IgG and IgM levels aswell as an increase inNAb titers pre- and postinfluenza vaccination.
Notably, NAb titers of most HCT patients did not rise to a protective level postvaccination. CD41 T cell
expression of CD154 and cytokine responses were significantly reduced in HCT recipients compared to
healthy adults. A lack of B cell reconstitution and dysfunctional CD4 T cell costimulation (as marked by low
CD154 expression) is associated with low NAb levels postvaccination in HCT patients.
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Hematopoietic cell transplant (HCT) recipients un-
dergo ablative chemotherapy prior to transplantation,
losing all T cell and most B cell memory. Some donor
immunity is transferred to the recipient, but revaccina-
tion is required in the recipient to establish memory
responses against common opportunistic infections
regardless of the donor’s immune status [1-3]. The
recipient must wait for immune reconstitution to
occur and then build immunity through vaccination or1Division of Translational Vaccine Research, Department
ology ; 2Division of Biostatistics, Department of Infor-
n Sciences; 3Division of Clinical Research Information
gement, Department of Information Sciences; and 4Dep-
nt of Hematology and Hematological Transplantation,
an Research Institute of the City of Hope National
al Center, Duarte, California.
isclosure: See Acknowledgments on page 531.
dence and requests: Don J. Diamond, PhD, Division of
lational Vaccine Research, Department of Virology,
an Research Institute of the City of Hope, 1500 East
e Road, Duarte, CA 91010 (e-mail: DDiamond@coh.org).
arch 1, 2010; accepted April 26, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.04.015reexposure [4,5]. The appropriate time for vaccination
to generate protective immunity during immune
reconstitution has been studied for some pathogens
[2,6,7], but is less well understood for others, including
influenza [8-13]. During immune reconstitution
following HCT, CD3-positive lymphocytes are devel-
oped 6 to 8 weeks posttransplant in autologous HCT
and approximately 12 weeks in allogeneic HCT [14].
CD8 T cell repopulation occurs faster (by about 4
months) than CD4 T cell repopulation, which can take
as long as 6 to 9 months [14]. B cell levels are restored
quickly and close to normal 1 to 2 months after trans-
plant [14]; however, humoral immune dysfunction
remains for 18 to 24 months [15]. Although B cells
have reconstituted to levels sufficient to support influ-
enza vaccination at 6 months posttransplant [7], a lack
of expression of adhesions molecules on B cells [16]
and a lack of functional T helper cells after transplant
leads to a failure to produce protective levels of neutral-
izing antibody (NAb) titers postvaccination.
Important in generating a protective immune
response postvaccination is the activation of CD4
T cells necessary to costimulate B cells and generate
protective antibodies [17-20]. CD154 expression on
helper CD4 T cells is necessary for B cells to
produce a protective NAb titer [17,19,20]. Our
studies and others show that HCT patients produce
Biol Blood Marrow Transplant 17:524-533, 2011 525CD154 a Marker of Flu Vaccine Responsenonprotective NAb levels, leaving transplant patients
susceptible to influenza infection [6,9,21-25].METHODS
Subject Recruitment
Healthy individuals were recruited during the City
of Hope (COH) employee influenza vaccination cam-
paign. The COH institutional review board approved
the research protocol and informed consent was
obtained from all subjects prior to participation in
the study. HCT patients were recruited to participate
in the study, and informed consent was obtained
pretransplant by the transplant nurse coordinator.Flu Vaccination
Healthy subjects were vaccinated at COH with the
2007-2008 seasonal flu vaccine. HCT patients were
vaccinated at COH with the 2008-2009 seasonal
vaccine according to physician orders. It was our orig-
inal intent to accrue patients in the same flu season as
we accrued healthy volunteers. However, we were only
able to follow 2 HCT patients during the 2007-2008
flu season. Accrual was better in the 2008-2009 flu
season and represents the data presented here.Blood Draws
Consented individuals had 30 to 40 mL of blood
drawn at the COH General Clinical Research Center
prior to flu vaccination (d0) and at days 30, 90, and
180 (d30, d90, D180) postvaccination. Serum samples
were used for IgG, IgM, and NAb studies, whereas pe-
ripheral blood mononuclear cells (PBMC) were puri-
fied from whole blood and used in CD4 T cell assays.Specimen Preparation
Five milliliters of blood was drawn into a red top
BD vacutainer for serum collection. Serum from
HCT patients was collected d0 and at d30 and d180
postvaccination for HCT patients and d0 and at
d180 postvaccination for healthy adults. The tubes
were centrifuged and serum removed. Serum was
aliquoted and stored at 280C until run on ELISA
or used in hemagglutination inhibition assays (HAI).
A total of 30 to 40 mL of blood was drawn into BD
vacutainers containing 86 USP units of sodium hep-
arin. Whole blood was then mixed 1:1 with phosphate-
buffered saline (PBS) and layered over ficoll-paque
(GE Healthcare, Piscataway, NJ). PBMC were
isolated by centrifugation over the ficoll for 30 minutes
at 1200 r.p.m. PBMC were removed and washed twice
in PBS. PBMC were stored in fetal bovine serum con-
taining 10% dimethyl sulfoxide in liquid nitrogen until
assay. Frozen cells were used with no detriment to thedetection of activation markers and batching samples
together reduces the interassay variability.
IgG and IgM Testing
IgG and IgM specific for Influenza A were mea-
sured using ELISA (IBL-America, Minneapolis,
MN). Samples were tested in duplicate according to
the manufacturer’s protocol.
Hemaglutination Inhibition Assays (HAI)
Components for the 2007-2008 and 2008-2009 flu
seasons were obtained from the World Health Organ-
ization’s (WHO) Influenza reagent program via the
Centers for Disease Control (CDC) and Prevention
in Atlanta, GA. Turkey erythrocytes were obtained
from Bio-Link Inc. (Lisle, IL). HAI testing was per-
formed using the WHO protocol for 2007-2008 or
2008-2009 Influenza reagent kit for identification of
influenza isolates. The virus strains in the 2007-2008
influenza vaccines were A/SolomonIslands/3/2006
(H1N1), A/Wisconsin/67/2005 (H3N2), and B/Ma-
laysia/2506/2004. The virus strains in the 2008-2009
influenza vaccines were A/Brisbane/59/2007 (H1N1),
A/Brisbane/10/2007 (H3N2), and B/Florida/4/2006.
Serum samples were incubated with receptor destroy-
ing enzymes (Cholera filtrate, Sigma-Aldrich, St.
Louis, MO) overnight at 37C. The samples were di-
luted in physiologic saline to a final concentration of
1:10 and then titrated down to 1:1280. The samples
were incubated with turkey erythrocytes for 1 hour be-
fore being assayed for NAb concentrations.
CD4 T Cell Activation Assay
PBMC were thawed and plated at 1 106 cells/well
in a 96-well plate in RPMI containing 10% FBS. A total
of 2 mL each of CD28 and CD49b antibodies (Becton-
Dickinson, Franklin Lakes, NJ) were added to each
well. Media containing 0.5% DMSO was used for
mock stimulation and 50 mL of the matched year influ-
enza vaccine was added to wells for stimulation. CD154
PE (e-Bioscience, San Diego, CA) was added to all
wells and plates were incubated at 37C for 1 hour.
Golgistop (Becton-Dickinson) and Golgiplug
(Becton-Dickinson) were added after 1 hour and incu-
bation continued overnight. The following day cells
were washed in PBS 1 0.5% bovine serum albumin
(BSA). CD4 PerCP-Cy5 (e-Bioscience) antibody was
then added and incubated on ice for 30 minutes
followed by 2 washes in PBS 1 0.5% BSA. PBMC
were then resuspended in 100 mL of BD Cytofix/Cyto-
perm (Becton-Dickinson) for 20 minutes on ice
followed by 2 washes in BD Perm/Wash
(Becton-Dickinson). Antibodies to IFN-g and
TNF-a (e-Bioscience) were then added at the manu-
facturer’s recommended concentration for 30 minutes
on ice. Cells were washed twice more in PBS 1 0.5%
Table 1. Demographics of Participating Subjects
Healthy Subjects
Sex Subjects Percent
Females 43 75
Males 14 25
Total 57
Age range in years
Age at vaccination (24-70)
HCT Patients
Sex Subjects Percent
Females 20 57
Males 15 43
Total 35
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(Becton-Dickinson). Data analysis was performed
using FlowJo software (TreeStar, Ashland, OR).
Statistical Analyses
To compare data between healthy and HCT sub-
jects nonparametric statistical tests were used. P-values
were calculated using the Mann-Whitney test or 2-way
nonparametric analysis of variance (ANOVA) analogs
as indicated in the text and figure legends. The
Kruskal-Wallis test was used to compare the overall
levels of CD154, TNF-a, and IFN-g produced in
healthy subjects to HCT patients.Age range in years
Age at transplant (25-65)
Days Range of Days
Median No. of Days
Posttransplant at
vaccination
255 (20-443)
Disease Category Subjects Percent
AML 5 14
Multiple Myeloma 6 17
NHL 7 20
Other 17 49
Autologous 18 51
Allogeneic 17 49
Sib 2 12
MUD 6 35
Related match 9 53
AML indicates acute myelogenous leukemia; NHL, non-Hodgkin
lymphoma; MUD, matched unrelated donor; HCT, hematopoietic cell
transplant.RESULTS
Subject Characteristics
Table 1 shows the demographics of both healthy
subjects and HCT patients. The ages and sexes
between the 2 groups were similar (Table 1). Our study
design left the day posttransplant that vaccination
occurred at the discretion of the treating physician,
and thus patients were vaccinated over a large range of
time posttransplant. The median number of days
between transplant and vaccination was 255 days, indi-
cating that the majority of patients were vaccinated
according to CDC recommended guidelines of vaccina-
tion.180 days posttransplant [7,26]. It is believed that
vaccination 180 days posttransplant should allow for
sufficient B and T cell reconstitution to provide
protection from influenza sequelae [7]. Because recon-
stitution is delayed in HCT patients who develop
chronic graft-versus-host disease (GVHD) or are
treated with rituximab [15,27] we removed those
patients from the analysis. Sixteen of 17 alloHCT
patients were on prophylaxis to prevent the
development of acute GVHD (aGVHD). Prophylaxis
consisted of treatment with FK-506, Sirolimus, and/
or methotrexate [MTX]). The mean time from comple-
tion of GVHD prophylaxis and vaccination was 189
days. When analyzing the data we found no statistical
differences (Mann-Whitney test) in the data obtained
from allo- versus auto-HCT patients (data not shown).
Therefore, in our cohort we combined data from all
HCT patients for analysis. There is no evidence at
this time that GVHD prophylaxis impacted vaccination
responses. The effects of steroid treatment will be
examined in future studies, and patients receiving
steroid treatment are not included in the study cohort.
Influenza A IgG and IgM Levels Postvaccination
Sera from HCT and healthy subjects taken pre- and
postvaccination were tested for influenza A IgG and
IgM levels using ELISA. Figure 1 top panels show
the IgG and IgM responses for HCT patients and thebottom panels show the results for healthy volunteers.
Healthy subjects and HCT patients both showed a sig-
nificant increase in IgG levels postvaccination com-
pared to prevaccination (Figure 1). Mann-Whitney
tests showed a high level of significance in comparing
influenza A IgG (P\ .001) and IgM (P\ .001) levels
pre- and postvaccination in healthy subjects. There
was a significant change in IgG levels of patients at
d30 (P\ .05) and d180 (P\ .05) postvaccination com-
pared to d0 levels. However, the mean level of IgG was
significantly decreased in patients compared to healthy
controls as measured by a Kruskal-Wallis test (P\.01).
The influenza A IgM levels of HCT patients showed
a significant increase in IgM levels (P\.01) at d30 post-
vaccination, but IgM levels had returned to baseline by
d180 postvaccination. This is in direct contrast to the
d180 IgM levels seen in healthy subjects.
Influenza HAI Assays
Qualitative antibody data was determined by mea-
suring the titers of NAb produced postvaccination.
HAI assays against each flu strain in the 2007-2008
(healthy subjects) or 2008-2009 (HCT patients) were
performed (see Methods for full strain identification).
Figure 1. Influenza A IgG and IgM levels in hematopoietic cell transplant (HCT) patients (A & B) and healthy adults (C & D). Serum from day 0 (d0)
prevaccination or day 180 (d180) postvaccination for healthy adults or d0 and day 30 (d30) and d180 postvaccination for HCT patients was tested by ELISA
for IgG and IgM specific for Influenza A. Black error bars represent the standard deviation from the mean (dashed bar). The P-values are calculated using
a two-tailed Mann-Whitney test. Healthy subjects showed sustained increases in both IgG and IgM levels at d180 postvaccination. In HCT patients IgG and
IgM levels were elevated at d30 postvaccination, but for IgM the Ab level had returned to baseline by d180 post-vaccination. *P\ .05, ***P\ .001.
Biol Blood Marrow Transplant 17:524-533, 2011 527CD154 a Marker of Flu Vaccine ResponseFigure 2 shows the HAI results for healthy volunteers
against the 2007-2008 influenza (A)H1N1, (A)H3N1,
and (B)Malaysia strains. Figure 3 shows the HAI
results for HCT patients against the 2008-2009 influ-
enza (A)H1N1, (A)H3N2, and (B)Florida strains. AFigure 2. Hemagglutination inhibition assay (HAI) measure of neutralizing an
2007-2008 flu season. Healthy subject serawas tested for NAb titer at d0 and at
flu vaccine antigens (A)H1N1 (Panel A), (A)H3N2 (Panel B), and (B)Malaysia (Pa
the mean (dashed bar). The dotted black line represents a titer of 40, which iNAb titer above 40 is considered protective. All
healthy adults showed some increase in NAb titers 6
months postvaccination compared to prevaccination
levels. The majority of healthy adults had NAb titers
above the protective level at 6 months postvaccinationtibody (NAb) levels in healthy subjects pre- and postvaccination for the
d180 postvaccination. NAb titers measured were against the 2007-2008
nel C) flu strains. Black error bars represent the standard deviation from
s considered protective. ***P\.001, P 5 2-tailed Mann-Whitney test.
Figure 3. HAI assay measure of NAb levels in HCT patients pre- and postvaccination during the 2008-2009 flu season. NAb titer from serum was
measured at d0 and at d30 and d180 postvaccination. HCT patient sera was measured against the 2008-2009 flu vaccine antigens for (A)H1N1 (Panel
A), (A)H3N2 (Panel B), and (B)Florida (Panel C) flu strains. Black error bars represent the standard deviation from the mean (dashed bar). The dotted
black line represents a titer of 40, which is considered protective. *P\.05, **P\.01, P 5 2-tailed Mann-Whitney test.
528 Biol Blood Marrow Transplant 17:524-533, 2011A. Seidel et al.(Figure 2). Contrary to what was seen in healthy adults
the NAb titers seen in HCT recipients (Figure 3) even
d30 postvaccination were rarely above the protective
level.CD4 T Cell Assays for CD154 Expression
Based on previous studies [6,9,28] it is evident
that simply measuring antibody responses to flu
vaccination does not provide a comprehensive picture
of the immune response, especially in immune
compromised individuals. One reason for the poor
NAb response shown in Figure 3 is the result of weak
or no costimulation from CD4 helper T cells in HCT
patients. CD154 is a marker of newly activated CD4
T cells and is important in B cell costimulation
[19,29,30]. CD154 (Figures 4 and 5), TNF-a, and
IFN-g (Figure 6) expression were measured on CD41
T cells from healthy and HCT subjects. CD154 expres-Figure 4. CD154 expression on CD4 T cells after stimulation with inactivat
pression was measured by flow cytometry after 18 hours of stimulation with
expression was then calculated in terms of the absolute number of CD4 T ce
from the mean. The P-values were determined using a 2-way ANOVA. *P\.0sion on CD41 T cells postvaccination stimulated with
flu vaccine showed a significant increase (using a 2-
way ANOVA) compared to prevaccination samples in
both healthy and HCT subjects 1 month postvaccina-
tion (Figure 4). Figure 4B shows the CD154 response
in HCT patients prior to vaccination, and at d30, d90,
and d180 postvaccination. CD154 levels were signifi-
cantly higher at d30 postvaccination only compared to
d0 in HCT patients. When simultaneously comparing
all of the time points in both the mock and flu vaccine
treatment groups, the 2 groups were significantly differ-
ent from each other using a Kruskal-Wallis test (P\
.0001; data not shown), indicating the measured levels
of CD154 were above the background for the assay.CD154 Expression on CD4 T Cells
To determine the expression level of CD154 on
a per cell basis, the median fluorescence intensityed trivalent flu vaccine in healthy (A) and HCT (B) subjects. CD154 ex-
mock diluent or inactivated flu virus (matched annual vaccine). CD154
lls at each time point. Black error bars represent the standard deviation
5, **P\.01, ***P\.001.
Figure 5. Comparison of median fluorescence intensity (MFI) of CD154 on healthy subjects versus HCTrecipients. (A) The MFI of CD154 on the cell
surface after overnight stimulation with flu vaccine is shown. The P-values represent 2-tailed Mann-Whitney test where **P\.01, ***P\.001. HCT
patients show an attenuated CD154 expression level. (B) The absolute CD4 T cell count of the patients tested is graphed to show CD4 T cell
reconstitution over time. There was no statistically significant difference in the mean absolute CD4 T cell count after vaccination.
Biol Blood Marrow Transplant 17:524-533, 2011 529CD154 a Marker of Flu Vaccine Response(MFI) of CD154 on CD4 T cells was graphed
(Figure 5A) for both healthy and HCT subjects. The
MFI of CD154 did not change postvaccination in
HCT patients, but it did increase in healthy subjects.
Using a Kruskal-Wallis test to compare the levels of
all mock time points stimulated CD4 T cells to all inac-
tivated flu virus stimulated time points yielded a signif-
icant difference in both the healthy and patient
populations (P\.0001; data not shown). This indicates
that the CD154 MFI observed on stimulated CD4 T
cells is above the background level seen with mock
stimulation of CD4 T cells. Comparing the MFI of
CD154 between healthy and HCT patients with
Mann-Whitney tests showed a significant decrease in
CD154 levels of HCT patients at d30, d90, and d180
postvaccination (Figure 5A). Not only is the magnitude
of CD4 T cells responding to flu vaccination attenu-
ated in HCT recipients, but Figure 5A shows that the
MFI of CD154 on CD4 T cells from HCT patients is
significantly diminished compared to healthy subjects
postvaccination and does not correspond with overall
CD4 T cell reconstitution (Figure 5B). The absolute
CD4 T cell value for patients is shown in Figure 5B,
indicating the mean level of CD4 T cell reconstitution
was equivalent at all time points. TheP-values shown in
Figure 5A are the result of a 2-tailed Mann-Whitney
comparison. All time points in HCT patients showed
diminished CD154 expression when compared to the
same time point in healthy adults (Figure 5A).Figure 6. IFN and TNF double expression on CD4 T cells after stimulation
expression was measured by flow cytometry after 18 hours of stimulation wi
standard deviation from the mean. The P-values were determined using a 2-wCD4 T Cell Assays for Cytokine Production
Previous studies indicate that the most effective
T cells are capable of producing multiple cytokines
after antigenic stimulation [18,29,31,32]. Similar to
our CD154 findings, IFN-g/TNF-a expressing
double positive T cells were significantly attenuated
in HCT recipients compared to healthy adults
(Figure 6). Measuring IFN-g and TNF-a levels in
T cells after stimulation with killed flu virus from
the vaccine provides a measure of the functionality
of these CD4 T cells to recognize and respond to
subsequent flu infection [29,33-36]. TH2 CD4
T cell responses were evaluated using IL-4 antibody.
No changes in intracellular IL-4 levels were found
postvaccination compared to prevaccination (data
not shown). Others have shown that TH1 CD4
T cell responses are critical for antibody responses
that can control influenza virus [37,38]. There is no
current evidence that TH2 responses are important
in controlling flu infection.DISCUSSION
Although B cell reconstitution occurs early post-
transplant, there is a chronic dysfunction in B cells
and antibody responses [15,16]. Others have shown
that lagging development of adhesion molecules on B
cells can partially explain the longevity of B cellwith inactivated flu virus in healthy (A) and HCT (B) subjects. Cytokine
th mock diluent or inactivated flu virus. Black error bars represent the
ay ANOVA. *P\.05, **P\.01.
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ment with rituximab, steroid treatment, and incidence
of GVHD in allogeneic HCT patients leads to a longer
period of recovery for B cells to reach pretransplant
levels [15,27]. Finding ways to overcome B cell
dysfunction would increase the efficacy of vaccination
posttransplant. The data shows that reconstituted
CD4 T cells are also dysfunctional posttransplant
(Figures 4-6) and a lack of costimulation
(CD154) contributes to the longevity of the B cell
immune dysfunction. Low CD154 levels also
contribute to the lack of memory plasma cells
generated postvaccination, leading to decreased
durability of NAbs. The low levels of CD154
expression seen in HCT patients is associated with
the failure of HCT patients to generate protective
NAb titers to influenza postvaccination. The data
show that CD154 expression and CD4 T cell help is
required to promote influenza specific B cells to
produce NAb titers capable of protecting from
influenza infection postvaccination in HCT patients.
HCT patients have sufficient B cell reconstitution
to produce IgG and IgM after influenza vaccination as
illustrated in Figure 1 and as shown by others [3,15].
However, the antibody produced posttransplant is
not equivalent to the antibody produced in healthy
subjects as indicated by the low NAb levels shown in
Figure 3. Taken together, Figures 1-3 show that B
cells are present and capable of producing antibody
postvaccination, but the antibodies produced are not
protective from influenza infection. Routine B
lymphocyte counts are not performed on HCT
patients in our institution and this information is
lacking in our analysis of the patient subset, but
could be prospectively monitored in future studies.
Studies of vaccine immunogenicity and efficacy
across flu seasons show protective responses in around
65% to 70% of healthy adults across various flu
seasons [39,40]. Studies have shown that slight
variations in immunogenicity results from changes
in the yearly flu strain composition of the
vaccine, larger variability results from differences in
adjuvants and manufacturer [41-43]. Additionally,
live attenuated (LAV) versus inactivated trivalent
(TIV) causes large variation in immune responses
[41,44,45]. Because of viral shedding LAV, vaccine is
contraindicated for HCT patients [44,46]; thus, all
patients and healthy subjects included in our study
were vaccinated with TIV from the same
manufacturer. Although some of the differences we
see in HAI and CD154 levels between HCT patients
and healthy adults may be the result of changes in
the vaccine components from year to year, we believe
the incredibly low levels of NAbs and CD154 seen in
HCT patients can mostly be contributed to defects
in the ability of HCT reconstituting cells to respond
to vaccination. Controlling for differences inmanufacturer and TIV versus LAV is more
influential to consistent results than comparing
across flu seasons. Also of consideration is the
importance of previous vaccination on the response
to current vaccination.
There is little data available on the impact of pre-
vious vaccination on T cell responses but there are
reports of the effect of previous vaccination on B cell
responses [47]. Sasaki et al. [47] performed a direct
comparison of HAI response after vaccination with
either TIV, LAV, or no vaccination in previous years.
Sasaki and colleagues showed that previous vaccina-
tion with TIV lead to higher baseline HAI measures,
but to lower or decreased changes in HAI after second-
ary TIV or LAV vaccination. The vaccination history
of the healthy adults and HCT donors/HCT patients
participating in our study is unknown; however, inclu-
sion in our study required the 2008-2009 flu vaccine to
be the first flu vaccine received posttransplant for all
HCT patients. Although allo-HCT patients could
receive some preexisting immunity from the HCT
donor, we did not see excessively high prevaccination
NAb levels to indicate that immune memory was
passed on from the donor. The higher prevaccination
NAb levels shown in Figure 2 could be a result of
long-term B cell memory attributed to previous TIV
flu vaccination.
Further complicating the interpretation of our re-
sults is the impact of concurrent vaccinations. Healthy
subjects did not receive concurrent vaccinations at the
time of flu vaccination. Only 1 of 35 patients included
in our study received a concurrent vaccination on the
same day as they received the flu vaccine. This patient
received a pneumococcal pneumonia vaccine at the
same visit as their flu vaccine. Vaccination to other
agents could clearly muddle the results shown here;
however, in our cohort, patients who have documented
vaccinations in their COH record received those vacci-
nations at subsequent visits more than 6 months after
flu vaccination with the exception of the noted pneu-
mococcal vaccine stated before. Because subsequent
vaccinations occurred outside the scope of our study
we do not believe them to be complicating factors in
interpreting the data presented. We acknowledge
that some patients could have been vaccinated outside
of COH and we would not have knowledge of these
vaccinations. Every effort is made by phone and mail
to determine a complete vaccination record of partici-
pants after enrollment on study.
In a mouse model, Brown et al. [36] showed that
adaptive transfer of flu specific CD4 T cells along
with influenza specific B cells into naı¨ve mice provided
protection from subsequent lethal challenge with
influenza virus, when transfer of B cells alone did not
protect from death. Brown et al. [36] concluded that
when antigen specific CD4 T cells are present to cos-
timulate and drive B cells, higher levels of NAb titers
Biol Blood Marrow Transplant 17:524-533, 2011 531CD154 a Marker of Flu Vaccine Responseare produced and protection to influenza challenge is
established in a mouse model. Our data show that
the poor quality of influenza antibody response seen
after vaccination in HCT patients (Figure 3) is because
of a lack of CD4 T cell activation (Figure 4) and low
CD154 expression (Figure 5). Also in support of our
findings, Lee et al. [17] showed that the development
of influenza-specific IgG in mice lacking functional
CD4 T cell help could recover from a challenge with
influenza virus within the first 30 days of vaccination,
but that long-term antibody protection from influenza
challenge was lost. This study supports our finding
that HCT patients were able to develop some NAb ti-
ters (independent of CD4 T cell help) within the first
30 days postvaccination, but that by 6 months postvac-
cination IgG, IgM (Figure 1), and NAb responses
(Figure 3) diminish in the absence of functional CD4
T cell help. CD4 T cell costimulation via CD154 is
critical to developing a long-term protective NAb
response, and the lack of CD154 expression on CD4
T cells from HCT patients (Figure 5) explains the
lack of durability of NAb responses in HCT patients
(Figure 3) compared to healthy adults (Figure 2)
following influenza vaccination.
Eaton et al. [19] conducted an adaptive transfer
study between healthy aged and young mice. The
authors found that when CD4 T cells from the aged
mice were transferred into young healthy adult mice
the B cell responses to vaccination were impaired.
The authors were able to attribute this immune
dysfunction to low CD154 expression levels on CD4
T cells from the aged mice [19]. This finding on the
importance of CD154 expression in the healthy aged
mouse population supports our finding that low levels
of CD154 expression (Figures 4 and 5) correlate with
low NAb titers in HCT patients (Figure 3) postvacci-
nation. CD154 expression is critical to the efficacy of
vaccination in the elderly and in immunosupressed
populations such as HCT patients.
Similar to our results (Figure 6), Avetisyan et al. [8]
looked at IFN-g responses in HCT patients 4 weeks
postvaccination and found a 10- to 100-fold decrease
in the level of IFN-g measured by ELISPOT com-
pared to healthy adults. Our results confirm and extend
this finding, and suggest that solely looking at IFN-g
production may provide an incomplete profile of T
cell response to vaccination. Although the cytokine
responses measured in HCT patients (Figure 6) were
significantly increased postvaccination, the extremely
low levels of IFN-g and TNF-a expressed compared
to CD4 T cell expression levels in healthy subjects
indicates further immune dysfunction of CD4 T cells
in HCT patients. The attenuated cytokine response
of CD4 T cells posttransplant contributes to the
failure of HCT patients to mount protective immune
responses postvaccination. Using flow cytometry
permits examination of multiple parameters (CD154,IFN-g, TNF-a) of T cell activation and function in
a single cell after stimulation compared to ELISPOT.
Finding multiple indicators of CD4 T cell dysfunction
indicates that CD4 T cells in HCT patients posttrans-
plant are incapable of providing effector function or
the costimulation necessary for productive B cell
responses postvaccination.
The data show the importance of examining both
humoral and cellular immune responses posttransplant
to determine the appropriate time to provide vaccina-
tion and protection against influenza posttransplant.
Although it was previously known that HCT recipi-
ents do not produce equivalent antibody responses to
vaccination as healthy adults [6,9,22,23,48], little has
been written about the mechanism of this defect or
about alternate measures of protective immune
response postvaccination. The data show that
impaired functionality of CD4 helper T cells
generated postvaccination in HCT patients explains
the failed NAb response to flu vaccination. Without
sufficient costimulation via CD154 (CD40L) on
CD4 T cells, B cells do not produce protective levels
of NAb titers following vaccination in HCT patients.
Future studies, on a larger patient population, will
help to elucidate the important cofactors such as
GVHD, age at time of transplant, and steroid and
rituximab treatment, which may contribute to the
lack of B cell-generated NAb response seen in HCT
patients postvaccination. We have demonstrated the
importance of CD154 expression on activated CD4
T cells in inducing NAb postvaccination in HCT
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